These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33567855)

  • 1. Clinical Use of Cangrelor After Percutaneous Coronary Intervention in Patients Requiring Mechanical Circulatory Support.
    Katz A; Lewis TC; Arnouk S; Altshuler D; Papadopoulos J; Toy B; Smith DE; Merchan C
    Ann Pharmacother; 2021 Oct; 55(10):1215-1222. PubMed ID: 33567855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support.
    Pluenneke JC; Mohamed AM; Hayes CH; Berry TP; Thomas EL; Zhurav L; Kozinn JB; Haines MM; Welge JA
    J Cardiothorac Vasc Anesth; 2023 Dec; 37(12):2511-2516. PubMed ID: 37775345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual antiplatelet therapy in patients supported with venoarterial extracorporeal membrane oxygenation.
    Cohan D; Uricchio MN; Konopka CI; Montepara CA; Verlinden NJ
    Artif Organs; 2023 Oct; 47(10):1672-1677. PubMed ID: 37203212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
    Bowman S; Gass J; Weeks P
    Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet Function Testing to Guide Cangrelor Dosing in Patients with Temporary Mechanical Circulatory Support or as a Bridge to Procedure.
    Buck MM; Barry CI; Montepara CA; Verlinden NJ
    Clin Appl Thromb Hemost; 2024; 30():10760296241237228. PubMed ID: 38439661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone.
    Martin TC; Duewell BE; Juul JJ; Rinka JRG; Rein L; Feih JT
    J Cardiothorac Vasc Anesth; 2024 Jun; 38(6):1328-1336. PubMed ID: 38521630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-thrombotic Therapy With Cangrelor and Bivalirudin in Venoarterial Extracorporeal Membrane Oxygenation Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Experience.
    Baldetti L; Nardelli P; Ajello S; Melisurgo G; Calabrò MG; Pieri M; Scandroglio AM
    ASAIO J; 2023 Jul; 69(7):e346-e350. PubMed ID: 36490373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry.
    Rymer J; Pichan C; Page C; Alhanti B; Bhatt DL; Kochar A; Angiolillo DJ; Diaz M; Wimmer NJ; Waksman R; Ang L; Bach R; Jenkins R; El-Sabae H; Brothers L; Ohman EM; Jones WS; Washam JB; Wang TY; Narcisse D; Basir MB
    J Card Fail; 2024 Oct; 30(10):1233-1240. PubMed ID: 39389732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
    Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
    Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study.
    Johnson BV; Horton ER; Domenico C; Nathan AS; Fanaroff AC; Acker MA; Kolansky DM
    J Invasive Cardiol; 2021 Dec; 33(12):E998-E1003. PubMed ID: 34817395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL;
    J Am Coll Cardiol; 2017 Jan; 69(2):176-185. PubMed ID: 28081827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention.
    Hideo-Kajita A; Rogers T; Buchanan K; Iantorno M; Gajanana D; Ozaki Y; Dan K; Kolm P; Brathwaite E; Beyene S; Melaku G; Meirovich Y; Dheendsa A; Garcia-Garcia HM; Torguson R; Waksman R
    Am J Cardiol; 2019 Apr; 123(8):1228-1238. PubMed ID: 30738570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
    Angiolillo DJ; Bhatt DL; Steg PG; Stone GW; White HD; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Mahaffey KW; Harrington RA
    J Thromb Thrombolysis; 2015 Oct; 40(3):317-22. PubMed ID: 26024789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor use prior to left ventricular assist device surgery: a case series.
    Washam JB; Yerokun B; Patel CB; Welsby IJ; Milano CA; DeVore AD
    J Thromb Thrombolysis; 2018 Aug; 46(2):131-133. PubMed ID: 29860606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single stick access using a VA-ECMO arterial return cannula for coronary intervention in cardiogenic shock.
    Kapur NK; Hirst CS; Davila CD; Garcia R
    Catheter Cardiovasc Interv; 2021 Apr; 97(5):E673-E675. PubMed ID: 32583917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Yerasi C; Case BC; Chezar-Azerrad C; Forrestal BJ; Medranda GA; Shea C; Zhang C; Ben-Dor I; Satler LF; Bernardo NL; Hashim H; Garcia-Garcia HM; Waksman R
    Am Heart J; 2021 Aug; 238():59-65. PubMed ID: 33961829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.